Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

New York Lung Cancer Alliance, New York, NY 10024-5129, USA.
Drugs (Impact Factor: 4.13). 02/2007; 67(10):1403-10. DOI: 10.2165/00003495-200767100-00003
Source: PubMed

ABSTRACT Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40% bioavailability; thus, a dose of 80 mg/m(2) orally is the equivalent of 30 mg/m(2) intravenously, and 60 mg/m(2) orally is the equivalent of 25 mg/m(2) intravenously. Studies also concluded a lack of food effect on the administration of oral vinorelbine. In addition, no drug-drug interactions were found with a variety of commonly used antineoplastic agents.Vinorelbine, either orally or intravenously, has been investigated in randomised phase II trials as a single agent and in combination with cisplatin or carboplatin in patients with NSCLC. In general, response and survival results with oral vinorelbine appeared similar to the intravenous agent. Adverse-effect profiles were also similar for the two formulations. Clearly, the issue of venous irritation does not exist with oral vinorelbine; however, nausea and vomiting were more frequent when vinorelbine was administered orally compared with intravenously when no planned antiemetic therapy is given.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacokinetics and biodistribution of vinorelbine (VRB) delivered in a parenteral lipid emulsion (VLE) were evaluated, and compared with that of a commercial vinorelbine injectable solution (Navelbine (R) i.v., VS). After intravenous administration to rats at doses of 2.25, 4.5, and 9 mg/kg, the AUC(0-24 h) was significantly different (1.15 +/- 0.27, 2.65 +/- 0.82, and 8.18 +/- 1.10 mg/L/h for 2.25, 4.5, and 9 mg/kg, respectively), other pharmacokinetic parameters of VLE, such as the Cmax, CL, and Vss, were also dependent on the dose of VLE. The pharmacokinetics of VLE in rats was dose-dependent in the dosage range of 2.25-9 mg/kg. VLE exhibited significantly higher VRB concentration than that of VS at the initial time points, it also produced a higher AUC(0-24) (h), MRT and lower CL in comparison with VS. In beagle dogs, VLE exhibited pharmacokinetic bioequivalence to VS. The tissue distribution in mice of VLE was modified compared to VS, the AUC(0-48) (h) of VLE was grater in the liver, spleen, kidney and small intestine, but a little lower in the heart and lung.
    European Journal of Lipid Science and Technology 02/2011; 113(2). DOI:10.1002/ejlt.201000433 · 2.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. Vinorelbine can also be administered orally. However, the efficacy of orally administrated vinorelbine in adjuvant treatment of NSCLC is unknown. We assessed the overall survival (OS) and disease-free survival (DFS) of patients treated with adjuvant i.v. vinorelbine or p.o. vinorelbine, in combination with i.v. cisplatin. We reviewed two time-separated cohorts of patients referred to the Department of Oncology at Aarhus University Hospital (Denmark) from 2005 to 2012 for adjuvant chemotherapy after surgery for NSCLC. Of the 265 patients included in this study, 126 patients received i.v. and 139 received p.o. vinorelbine/cisplatin. The two groups were comparable with respect to important baseline characteristics. Median OS for all patients was 78.7 months and the median DFS was 35.7 months. No statistically significant difference in OS or DFS for patients treated with i.v. or oral vinorelbine was detected. The DFS rates of the two groups were comparable across all variables in subgroup analysis. In conclusion we observed that intravenous or oral administration of vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Lung Cancer 02/2015; 88(2). DOI:10.1016/j.lungcan.2015.02.010 · 3.74 Impact Factor
  • Source


Available from